GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortrea Holdings Inc (NAS:FTRE) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)

Fortrea Holdings (Fortrea Holdings) Total Revenue Growth Rate (Future 3Y To 5Y Est) : 2.70 (As of May. 13, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Fortrea Holdings Total Revenue Growth Rate (Future 3Y To 5Y Est)?

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the average growth rate of total revenue estimates over a 3-year to 5-year period.

As of today, Fortrea Holdings's Total Revenue Growth Rate (Future 3Y To 5Y Est) is 2.70.

Competitive Comparison of Fortrea Holdings's Total Revenue Growth Rate (Future 3Y To 5Y Est)

For the Biotechnology subindustry, Fortrea Holdings's Total Revenue Growth Rate (Future 3Y To 5Y Est), along with its competitors' market caps and Total Revenue Growth Rate (Future 3Y To 5Y Est) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fortrea Holdings's Total Revenue Growth Rate (Future 3Y To 5Y Est) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortrea Holdings's Total Revenue Growth Rate (Future 3Y To 5Y Est) distribution charts can be found below:

* The bar in red indicates where Fortrea Holdings's Total Revenue Growth Rate (Future 3Y To 5Y Est) falls into.


Fortrea Holdings  (NAS:FTRE) Total Revenue Growth Rate (Future 3Y To 5Y Est) Explanation

Total Revenue Growth Rate (Future 3Y To 5Y Est) is the growth rate of total revenue estimates over a 3-year to 5-year period. This data is provided directly by our trusted data vendors Refinitiv or Morningstar.

In situations where both vendors do not directly provide the growth rate data, we use the most recent annual revenue for the current year and estimated future revenue figures provided by the vendor to calculate the growth rate. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average total revenue estimates growth rate.

Fortrea Holdings Total Revenue Growth Rate (Future 3Y To 5Y Est) Related Terms

Thank you for viewing the detailed overview of Fortrea Holdings's Total Revenue Growth Rate (Future 3Y To 5Y Est) provided by GuruFocus.com. Please click on the following links to see related term pages.

Fortrea Holdings (Fortrea Holdings) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortrea Holdings Inc (NAS:FTRE) » Definitions » Total Revenue Growth Rate (Future 3Y To 5Y Est)
Comparable Companies
ZLAB MLTX DNLI BHVN MDGL NTLA ARWR RVMD IBRX DNA OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
K67:Germany
Address
8 Moore Drive, Durham, NC, USA, 27709
Website
https://www.fortrea.com
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after LabCorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
Executives
Thomas Pike officer: Chief Executive Officer C/O ACCENTURE, 161 N. CLARK STREET, 23RD FLOOR, CHICAGO IL 60601
Peter M Neupert director 13920 SE EASTGATE WAY, STE 300, BELLEVUE WA 98005
Betty D Larson director GE HEALTHCARE TECHNOLOGIES INC., 500 W. MONROE, CHICAGO IL 60661
R Andrew Eckert director THREE RAVINIA DRIVE, ATLANTA GA 30346
Edward A Pesicka director 9120 LOCKWOOD BLVD, MECHANICSVILLE VA 23116
Amrit Ray director 60 LEVERONI COURT, NOVATO CA 94949
Amanda M. Warren officer: Chief Accounting Officer 8 MOORE DRIVE, DURHAM NC 27703
David Ross Smith director 251 BALLARDVALE STREET, WILMINGTON MA 01887
Van Der Vaart Sandra D director, officer: President and Secretary 531 SOUTH SPRING STREET, BURLINGTON NC 27215
Glenn A Eisenberg director, officer: Executive Vice President P O BOX 1017, CHARLOTTE NC 28201-1017
James S. Hanson officer: General Counsel 79 TW ALEXANDER DRIVE, 4501 RESEARCH COMMONS, SUITE 100, RESEARCH TRIANGLE PARK NC 27709
Laboratory Corp Of America Holdings 10 percent owner 358 S MAIN ST, BURLINGTON NC 27215
Jill G. Mcconnell officer: Chief Financial Officer 8 MOORE DRIVE, DURHAM NC 27703
Mark A. Morais officer: Chief Operating Officer 8 MOORE DRIVE, DURHAM NC 27703
Robert S. Pringle officer: Treasurer 531 SOUTH SPRING STREET, BURLINGTON NC 27215